Iovance Biotherapeutics, Inc.

NasdaqGM:IOVA Stock Report

Market Cap: US$913.0m

Iovance Biotherapeutics Future Growth

Future criteria checks 5/6

Iovance Biotherapeutics is forecast to grow earnings and revenue by 59.9% and 31.3% per annum respectively. EPS is expected to grow by 65.9% per annum. Return on equity is forecast to be -14.9% in 3 years.

Key information

59.9%

Earnings growth rate

65.86%

EPS growth rate

Biotechs earnings growth23.6%
Revenue growth rate31.3%
Future return on equity-14.94%
Analyst coverage

Good

Last updated07 Nov 2025

Recent future growth updates

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results

Nov 08
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 02
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price

Recent updates

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results

Nov 08
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Aug 21

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth

Jul 22
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth

Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues

May 16
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues

News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat

May 13
News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat
User avatar

US Launch And Global Expansion Will Create New Opportunities

The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.

Iovance Biotherapeutics: Only For The Brave

Apr 22

Iovance: The Company Makes It Hard To Estimate Revenue Growth

Mar 18

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 02
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price

Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)

Feb 28

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Jan 11
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't

Dec 17

Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity

Nov 11

Iovance Biotherapeutics: Moving To The Next Phase

Oct 03

Iovance Therapeutics: Historic Product, Tough Commercial Outlook

Sep 06

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Aug 11

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Jun 26

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Earnings and Revenue Growth Forecasts

NasdaqGM:IOVA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027623-1041N/A8
12/31/2026424-247-127N/A11
12/31/2025260-382-311N/A11
9/30/2025250-398N/AN/AN/A
6/30/2025242-390-324-303N/A
3/31/2025213-375-348-334N/A
12/31/2024164-372-364-353N/A
9/30/202491-410-374-364N/A
6/30/202433-440-400-389N/A
3/31/20242-450-405-384N/A
12/31/20231-444-384-362N/A
9/30/20231-433-377-356N/A
6/30/20230-419-355-335N/A
3/31/2023N/A-412-333-319N/A
12/31/2022N/A-396-313-293N/A
9/30/2022N/A-390-294-269N/A
6/30/2022N/A-376-296-263N/A
3/31/2022N/A-358-278-239N/A
12/31/2021N/A-342-266-228N/A
9/30/2021N/A-311-290-237N/A
6/30/2021N/A-284-281-220N/A
3/31/2021N/A-265-259-202N/A
12/31/2020N/A-260-252-205N/A
9/30/2020N/A-255-223-196N/A
6/30/2020N/A-246-208-198N/A
3/31/2020N/A-230-202-195N/A
12/31/2019N/A-198-166-159N/A
9/30/2019N/A-167-140-137N/A
6/30/2019N/A-151N/A-122N/A
3/31/2019N/A-134N/A-112N/A
12/31/2018N/A-124N/A-101N/A
9/30/2018N/A-117N/A-91N/A
6/30/2018N/A-105N/A-84N/A
3/31/2018N/A-98N/A-78N/A
12/31/2017N/A-92N/A-79N/A
9/30/2017N/A-82N/A-70N/A
6/30/2017N/A-128N/A-61N/A
3/31/2017N/A-116N/A-47N/A
12/31/2016N/A-102N/A-33N/A
9/30/2016N/A-95N/A-27N/A
6/30/2016N/A-34N/A-19N/A
3/31/2016N/A-29N/A-19N/A
12/31/2015N/A-28N/A-18N/A
9/30/2015N/A-24N/A-15N/A
6/30/2015N/A-19N/A-13N/A
3/31/2015N/A-15N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IOVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: IOVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IOVA is expected to become profitable in the next 3 years.

Revenue vs Market: IOVA's revenue (31.3% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: IOVA's revenue (31.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IOVA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/09 02:33
End of Day Share Price 2025/11/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Iovance Biotherapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Madhu KumarBaird
Peter LawsonBarclays